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Results After multivariate adjustment for age, smok-
ing, hypertension, sex, body mass index and an interaction 
term (coffee*visit), coffee drinkers did not have a statisti-
cally significantly different kidney size compared to non-
coffee drinkers (difference of −33.03  cm3 height adjusted 
TKV, 95% confidence interval (CI) from −72.41 to 6.34, 
p = 0.10). After the same adjustment, there was no statis-
tically significant difference in eGFR between coffee and 
non-coffee drinkers (2.03  ml/min/1.73  m2, 95% CI from 
−0.31 to 4.31, p = 0.089).
Conclusion Data derived from our prospective longitudi-
nal study do not confirm that drinking coffee is a risk factor 
for ADPKD progression.
Keywords ADPKD · Coffee · Epidemiology · Kidney 
volume · Renal function decline · Progression
Introduction
Belibi and colleagues reported in 2002 results derived from 
in  vitro experiments of human polycystic kidney disease 
(PKD) cells exposed to caffeine [1]. Caffeine activated pro-
proliferative signalling pathways and increased transepi-
thelial fluid secretion in murine PKD cells and the authors 
concluded that caffeine is a risk factor for the promotion 
of cyst enlargement in patients with autosomal dominant 
PKD (ADPKD) [2]. Caffeine raises intracellular adenosine 
3′:5′-cyclic monophosphate (cAMP) levels by competi-
tively and non-selectively inhibiting cyclic nucleotide phos-
phodiesterase. These groups of enzymes degrade the phos-
phodiester bond in the second messenger cAMP molecules. 
For more than 10 years, intensive research has revealed 
that increased levels of intracellular cAMP causes ADPKD 
progression by stimulating transepithelial secretion and 
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proliferation, thus further fostering the persuasion that caf-
feine consumption accelerates ADPKD progression [3, 4]. 
Since then, ADPKD experts and ADPKD patient organiza-
tions have advocated to minimize caffeine intake.
However, there is little evidence on the effect of caffeine 
in patients with ADPKD and only cross-sectional studies 
are available so far. In 2012, the results of a cross-sectional 
study in ADPKD and healthy volunteers investigating 
the difference in caffeine intake and renal volume were 
reported [5]. Vendramini and colleagues did not identify an 
association between caffeine intake and kidney size, but the 
intake of caffeine was much lower among ADPKD patients 
than healthy volunteers. Possibly the observed caffeine con-
sumption difference among ADPKD patients and healthy 
volunteers was due to the conviction in the ADPKD com-
munity that caffeine might be toxic for ADPKD patients, 
although these concerns were based solely on in  vitro 
human cell experiments [6].
The relentless progression of ADPKD and the lack of 
effective therapies until recently has inclined the majority 
of physicians to advocate minimization of caffeine con-
sumption despite the absence of clinical data supporting 
their advice. In fact, cohort studies in human beings repeat-
edly showed a beneficial effect of coffee consumption on 
various outcomes. Coffee consumption has been associ-
ated with decreased mortality in a meta-analysis of nearly 
1 million subjects in 21 different independent studies [3, 7]. 
Coffee drinking’s beneficial effects have been identified for 
various diseases, including cardiovascular and kidney dis-
eases [8–10].
Since the current evidence base is very weak, our aim 
was to assess the longitudinal association of coffee con-
sumption and the progression of disease in patients affected 
by ADPKD.
Methods
Study design and participants
Patients were eligible for our analysis if they were enrolled 
from 2006 to 2014 in the Swiss ADPKD cohort and if 
they had not been treated with possible disease modifying 
drugs (e.g. sirolimus, everolimus, tolvaptan, and somato-
statin analogues). Patients had a proven ADPKD diagno-
sis, were between 18 and 60 years old and had an estimated 
glomerular filtration rate (eGFR) >30  ml/min/1.73  m2 at 
enrolment. All patients provided written informed consent 
and the local ethics committee approved the study (EK-
number 1178). Possible serious adverse events and adverse 
events were reported to the study investigator at least at 
every study visit. The enrolled patients had a minimum of 
1 and a maximum of 8 follow-up visits (median 4) and a 
median follow-up time of 4.38 years (interquartile range 
IQR 2.16–6.1). At each study visit the medical history was 
obtained, including medication, complications related to 
ADPKD, and the daily consumption of caffeine [11]. We 
excluded 69 patients with less than 2 visits because our 
study focused on disease progression over time. This gave 
a total sample size of 151 patients with 687 observations.
Progression of disease
Our primary outcome for progression of disease was kid-
ney size by using height adjusted total kidney volume 
(htTKV) and the secondary outcome was the eGFR. The 
baseline visit and each follow-up visit included a meas-
urement of kidney size and function, using a standardized 
protocol. The magnetic resonance imaging (MRI) acqui-
sition consisted of breath-hold T1-weighted fast spoiled 
gradient echo sequence without fat suppression sequence 
(4 mm slice thicknesses) and trans-axial T2 weighted fast 
spin echo sequences. The total kidney volume was esti-
mated by hand contouring of all MRI slices. The observer 
was blinded to previous measurements. Manual volume 
segmentation was done with the Advantage Workstation 
4.4, GE Healthcare, Little Chalfont, UK [12]. At each study 
visit, serum creatinine was assessed with the use of the 
modified Jaffé method traceable to an isotope-dilution mass 
spectroscopy reference [13]. GFR was estimated by apply-
ing the chronic kidney disease-epidemiology (CKD-EPI) 
formula [14].
Coffee consumption
Coffee consumption was assessed at each visit according to 
the following categories: never drink coffee; drink <1 cup 
of coffee per day, 1–2 cups of coffee per day, 2–4 cups of 
coffee per day, and >4 cups of coffee per day. For the anal-
ysis, coffee consumption was summarised as a binary vari-
able: “no or <1 coffee a day” vs. “coffee drinkers”. If the 
information about coffee consumption was missing for a 
certain visit (number of missing values: 162), the last avail-
able information was used for the analysis. We also per-
formed a sensitivity analysis without imputation of missing 
values.
Potential confounders
We considered the following potential confounders that 
could bias the association of coffee consumption and pro-
gression of ADPKD: at each visit, anthropometric measure-
ment and laboratory examinations were performed includ-
ing height, weight and blood pressure measurement as well 
as various blood and urine tests. Body mass index (BMI) 
(kg/m2) was included as a continuous variable. Blood 
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pressure was measured in sitting position, twice at an inter-
val of 10 min, using an oscillometric blood pressure device 
(Boso-Medicus, Jungingen, Germany). The variable hyper-
tension was defined as either systolic blood pressure above 
140 mmHg, diastolic blood pressure above 90 mmHg and/
or taking antihypertensive medication. Smoking was sum-
marised as a binary variable: “yes” vs. “no”.
Statistical analysis
Baseline characteristics were expressed as proportions, 
mean ± standard deviation and median (interquartile range, 
IQR), depending on their distribution. The main model for 
the primary outcome htTKV was a linear mixed model, 
with htTKV as outcome and coffee consumption as expo-
sure, and adjustment for confounders (baseline age, sex, 
hypertension, smoking and BMI). We included a random 
intercept for each subject and a random slope for each 
subject over time in the mixed model. Most of the covari-
ates were time-varying (coffee, hypertension, smoking 
and BMI) except for two which were fixed (baseline age 
and sex) [15]. Mixed models allowed us to track subject-
specific change over time and take into account the fact 
that data from the same individual were not independent. 
p values of <0.05 were considered significant. Stata 13.1 
(StataCorp, College Station, TX, USA) was used for data 
analysis.
Results
Patient characteristics
At inclusion (from April 2006 to June 2014) all 220 
patients had a proven ADPKD diagnosis. After exclusion 
of 69 patients who did not make a minimum of 2 visits, 
the remaining 151 ADPKD patients, with 687 observa-
tions, were included in the analyses. At baseline, 101 (67%) 
patients were coffee drinkers and 50 (33%) did not drink 
coffee. The overall mean ± SD age was 32.8 ± 8.9 years, 
and 60 (40%) were female. Non-coffee drinkers com-
pared to coffee drinkers (Table  1) were younger (28 ± 8 
vs. 35 ± 8 years), had smaller kidneys at baseline (753 vs. 
1118 cm3), and better renal function (eGFR 95.8 ± 19.5 vs. 
88.2 ± 19.1 ml/min/1.73 m2). The majority of patients suf-
fered from hypertension: 26 (52%) of the non-coffee drink-
ers and 69 (68%) of the coffee drinkers.
Association of coffee consumption with kidney 
progression
We found in the adjusted mixed model for htTKV a smaller 
estimated kidney size among coffee drinkers than non-
coffee drinkers [(beta)Coffee = −33.13; 95% confidence 
interval (CI) from −72.52 to 6.34; p = 0.10] but the dif-
ference was not significant. The interaction between cof-
fee and time in years was also not statistically significant 
Table 1  Demographic, clinical, 
and laboratory data at enrolment 
(baseline) according to coffee 
consumption group
Characteristic Total
n = 151
Non-coffee drinkers
n = 50
Coffee drinkers
n = 101
Age, years 32.8 ± 9 27.92 ± 8 35.2 ± 8
Sex, n (%)
 Female 60 (40) 23 (46) 37(37)
 Male 91 (60) 27 (54) 64 (63)
BMI, kg/m2 (mean ± SD) (missing = 9) 24.04 ± 4 23.62 ± 4 25.38 ± 4
eGFR, ml/min/1.73 m2 (missing = 2)
 Mean ± SD 90.78 ± 19 95.8 ± 19 88.23 ± 19
 Median (IQR) 89.24 (78–104) 97.01 (82–113) 87.04 (75–102)
Smoking, n (%) 53 (36) 16 (33) 37 (37)
TKV,  cm3
 Mean ± SD 1050.8 ± 685 915.8 ± 632 1117.8 ± 703
 Median (IQR) 894.51 (576–1306) 752.56 (492–1038) 976.43 (603–1372)
htTKV,  cm3/m
 Mean ± SD 595.9 ± 382 519.3 ± 364 633.9 ± 87
 Median (IQR) 504.56 (333–732) 421.7 (268–613) 549.03 (353–762)
Hypertension, n (%) 95 (63) 26 (52) 69 (68)
Blood pressure, mmHg (missing = 2)
 Systolic (mean ± SD) 138.4 ± 14 136.5 ± 13 139.4 ± 15
 Diastolic (mean ± SD) 89 ± 10 86.2 ± 9 90.5 ± 11
Antihypertensive drugs, n (%) 107 (71) 32 (64) 75 (74)
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[(beta)Coffee*Visityr = 10.85; 95% CI from −1.89 to 23.58; 
p = 0.10], indicating only weak evidence for a steeper 
increase of htTKV in coffee drinkers over time. The time 
variable was significant in all analyses [(beta)Visityr = 49.32; 
95% CI from 35.49 to 63.10; p < 0.01]. Figure 1 illustrates 
the development of htTKV over time from the mixed model 
taking into account an interaction between time (in years) 
and coffee. The lower baseline values of coffee drinkers as 
well as the steeper slope over time are clearly visible.
A sensitivity analysis included the alternative time vari-
able “number of visits since enrolment” instead of time 
in years and “age” as a time-varying covariate (instead of 
age at baseline) and showed similar results (Table 2) to the 
main model. A repetition of the analysis for patients with 
more than 2 visits (i.e. subjects were omitted if they had 
made <3 visits) confirmed our results. An additional sensi-
tivity analysis without imputation of missing values for cof-
fee showed similar results and confirmed the main analysis 
(Supplementary data Table 1).
Association of coffee consumption with eGFR
The main mixed model for eGFR was adjusted for the same 
confounders as the model for htTKV (Table 3). We can see 
that eGFR was higher among coffee than non-coffee drink-
ers 2  ml/min/1.73  m2 [(beta)Coffee = 2.03; 95% −0.31 to 
4.38, p = 0.089]. However, this effect was again not signifi-
cant. Figure 2 illustrates our mixed model’s adjusted pre-
dictions of eGFR with 95% CI.
The sensitivity analysis with the time variable ‘number 
of visits since enrolment’ and adjusted for age as a time-
varying covariate (instead of age at baseline) showed simi-
lar results to the main analysis. As in the former section, 
the analysis for subjects with more than 2 visits (subjects 
were omitted if <3 visits were made) showed very similar 
results. An additional sensitivity analysis without replacing 
missing values for coffee confirmed the results of the main 
analysis (Supplementary data Table 2)
Discussion
In our prospective longitudinal study of an ADPKD cohort 
at an early stage of disease, we did not find a statistically 
significant association between coffee consumption and dis-
ease progression as measured by kidney volume and func-
tion. The main analyses were corroborated by the sensitiv-
ity analyses, which assessed if results changed by including 
predictors for ADPKD progression as time-varying covari-
ates. The examination of the relationships between htTKV 
and age as a time-varying covariate showed similar results 
for the slope whereas the interception point of the trajec-
tory lines was higher (approximately for 4 visits). Our find-
ings indicate that drinking coffee is unlikely to be a risk 
factor for disease progression in ADPKD patients.
One may speculate if coffee consumption even has some 
protective effect. The point estimates for kidney volume 
and function favour the coffee consumption group although 
not significantly so. The effect might change over time, as 
Figs. 1 and 2 show. The protective effect on kidney volume 
may diminish over time, whereas the effect of coffee con-
sumption on kidney function was constant over time.
In fact, cohort studies in human beings have well inves-
tigated the effect of coffee consumption on various out-
comes and repeatedly showed a beneficial effect. A com-
munity-based study from Hsu et al. investigated risk factors 
for CKD including coffee consumption. After adjustment, 
coffee consumption was associated with a lower risk of 
CKD [16]. Three large cohort studies published in 2014 
investigated the association between coffee consump-
tion and the incidence of kidney stones. Drinking coffee 
was independently associated with a lower risk of inci-
dent kidney stones [17]. Coffee consists of more than caf-
feine, it is also rich in antioxidants, to which many of its 
health benefits have been attributed [18]. Previous studies 
reported that coffee can have a positive effect on health and 
is a protective factor against diabetes, cancer (skin, breast, 
neck and head), stress, Parkinson’s disease and also heart 
disease [8–10]. Besides these observations, other stud-
ies have also reported negative effects of coffee consump-
tion on blood pressure, cholesterol, serum lipid levels, and 
insulin resistance [19–22]. A dose-response meta-analysis 
of 21 longitudinal studies with nearly 1,000,000 subjects 
showed a non-linear association between coffee and mor-
tality from all causes, cardiovascular disease and cancer. 
The highest risk reductions were observed by drinking 
four cups per day for all-cause mortality and three cups 
Fig. 1  Adjusted prediction of kidney size (height adjusted total kid-
ney volume, htTKV) with 95% confidence interval (CI), by coffee 
consumption group
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per day for cardiovascular mortality. Drinking coffee was 
not associated with increased mortality due to cancer [7]. 
Therefore, transferring the strong evidence of a protective 
effect of moderate coffee consumption vis-à-vis other dis-
eases may imply that drinking coffee could also be benefi-
cial for ADPKD patients in general, through its antioxidant 
and anti-inflammatory effects. Indeed, our results question 
the general recommendation to avoid drinking coffee for 
patients affected by ADPKD.
Currently, tolvaptan is available as a disease modi-
fying therapy in Japan, Canada, the United States and 
also in Europe, where it has recently been approved [23]. 
Before, only co-morbidities could be treated. Besides this 
new medical treatment, lifestyle factors are particularly 
important for ADPKD patients to reduce risk factors and 
strengthen resources that can help prolong and stabilize 
renal function until end-stage renal disease (ESRD). There-
fore, avoiding potential risk factors in lifestyle has been 
attributed an important role to delay the disease progres-
sion in patients with ADPKD.
Our results have to be interpreted in the context of the 
study design and setting. First, one limitation is the meas-
urement of coffee consumption as the only source of caf-
feine (e.g. no soda, black tea or energy drinks were evalu-
ated). Although it is difficult to capture coffee consumption 
differently, self-reported coffee consumption may be prone 
Table 2  Association of coffee consumption with adjusted kidney size (height adjusted total kidney volume, htTKV) over time (n = 148)
Main analysis: htTKV with visit in years and baseline age
Name Coefficient p 95% confidence interval (CI)
Fixed effects
 Intercept 222.19 0.14 From −76.86 to 521.25
 Coffee −33.13 0.10 From −72.52 to 6.34
 Visityr 49.32 <0.01 From 35.49 to 63.10
 CoffeeVisityr 10.85 0.10 From −1.89 to 23.58
 Sex −204.56 <0.01 From −316.18 to −91.19
 Age at baseline 17.30 <0.01 From 11.25 to 23.67
 BMI 4.78 0.08 From −0.57 to 10.14
 Hypertension −13.01 0.27 From −36.55 to 10.42
 Smoker −6.27 0.59 From −29.27 to 16.72
Group Name Variance
Random effect
 Patno Intercept 333.75 19.72
 Visityr 59.05 3.93
 Residual 47.43 1.77
Sensitivity analysis: htTKV with number of visits and age (time-dependent)
Name Coefficient p 95% CI
Fixed effects
 Intercept −2.67 0.99 From −296.45 to 291.10
 Coffee −66.63 0.02 From −123.85 to −9.42
 Visits (n) 12.67 0.01 From 2.73 to 22.61
 Coffeevisit 10.17 0.03 From 1.07 to 19.26
 Sex −189.02 <0.01 From −297.85 to −80.20
 Age 24.60 <0.01 From 18.93 to 30.27
 BMI 3.41 0.28 From −2.78 to 9.60
 Hypertension −13.95 0.33 From −42.06 to 14.17
 Smoker −7.32 0.61 From −35.17 to 20.54
Group Name Variance
Random effect
 Patno Intercept 318.12 19.90
 Visits (n) 36.00 2.42
 Residual 57.43 2.16
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to misclassification, which may result in biased results. 
A limitation of our study is that self-reported coffee con-
sumption does not include other sources of caffeine like 
cola, energy drinks and black tea. Second, the number 
of follow-up visits may still be too low and we may have 
missed important long-term effects. Moreover, our subjects 
did not routinely undergo genetic testing during the study 
visits. However, based on the mean annual kidney growth 
rate of 9.43% and the median kidney size at baseline of 
894.51  cm3, it is very likely that the vast majority of our 
patients had PKD1 mutations.
Strengths of the presented study include its longitudinal 
design, the comprehensive statistical approach, the care-
ful measurement of kidney volume and function and the 
well-described cohort of untreated ADPKD patients at an 
early disease stage.
We believe that our results are a major step forward 
to elucidate the role of coffee consumption in ADPKD 
patients. The current evidence in patients with ADPKD 
including this longitudinal study does not suggest an 
association between coffee consumption and disease 
progression. It may be too early to frame a recommen-
dation for coffee consumption but it is time to at least 
lift the current recommendation to ‘strictly avoid’ cof-
fee consumption. In order to come up with stronger and 
evidence-based recommendations, additional studies are 
needed to strengthen the causal inference between cof-
fee consumption and disease progression. Additional 
Table 3  Adjusted association of coffee consumption with kidney function (estimated glomerular filtration rate, eGFR) over time (n = 148)
Main analysis: eGFR with visits in years and baseline age
Name Coefficient p 95% CI
Fixed effects
 Intercept 140.67 <0.01 From 124.38 to 156.96
 Coffee 2.03 0.089 From −0.31 to 4.38
 Visityr −2.13 <0.01 From −2.67 to −1.59
 Sex 0.48 0.854 From −4.69 to 5.67
 Age at baseline −1.34 <0.01 From −1.62 to −1.05
 BMI −0.17 0.418 From −0.58 to 0.24
 Hypertension −3.56 <0.01 From −5.98 to −1.15
 Smoker −1.81 0.141 From −4.22 to 0.59
Group Name Variance
Random effect
 Patno Intercept 14.35 0.92
 Visityr 2.44 0.23
 Residual 6.21 0.22
Sensitivity analysis: eGFR with visit number and age (time-dependent)
Name Coefficient p value 95% CI
Fixed effects
 Intercept 142.86 <0.01 From 126.92 to 158.79
 Coffee 2.13 0.079 From −0.24 to 4.52
 Visits (n) −0.46 <0.01 From −0.83 to −0.08
 Sex 0.08 0.975 From −5.04 to 5.21
 Age −1.37 <0.01 From −1.64 to −1.09
 BMI −0.18 0.385 From −0.59 to 0.23
 Hypertension −3.35 <0.01 From −5.78 to −0.92
 Smoker −1.51 0.223 From −3.93 to −0.92
Group Name Variance
Random effect
 Patno Intercept 13.97 0.93
 Visits (n) 1.56 0.14
 Residual 6.22 0.22
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prospective cohort studies would show how consistent 
the results are across studies, if there is a dose–response 
relationship, if there are subgroups of ADPKD patients 
who have different effects of coffee consumption, and 
if longer follow-up reveals a protective effect of coffee 
consumption.
In conclusion, this is the first prospective longitudinal 
study to investigate the long-term effect of coffee con-
sumption in an ADPKD population, carefully controlled 
for confounding. Our results suggest that drinking coffee 
is not a risk factor for ADPKD progression and question 
the current recommendations against coffee consumption.
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